Physiomics Share Price | |
---|---|
Price | 1.35 |
Bid | 0.00 |
Ask | 0.00 |
Change | 0.00 (0.00%) |
Volume | 0 |
Open | 0.00 |
High | 0.00 |
Low | 0.00 |
Prev. Close | 1.35 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 135.47m |
Market Capitalisation | £1.83m |
Market Size | 30,000 |
52 Week High | 4.20 |
52 Week High Date | 27-Mar-2023 |
52 Week Low | 0.925 |
52 Week Low Date | 09-Aug-2023 |
# Trades | 0 |
---|---|
Vol. Sold | 0 |
Sold Value | £N/A |
Vol. Bought | 0 |
Bought Value | £N/A |
PE Ratio | -2.755102 |
Earnings | -0.49 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
18-Mar-24 | 13:29:39 | 1.3475 | 18,257 | Sell* | 1.20 | 1.50 | 246.01 | O Ordinary |
18-Mar-24 | 11:29:33 | 1.3475 | 43,343 | Sell* | 1.20 | 1.50 | 584.05 | O Ordinary |
18-Mar-24 | 08:34:44 | 1.35 | 184,300 | Unknown* | 1.20 | 1.50 | 2,488 | O Ordinary |
18-Mar-24 | 08:34:22 | 1.34 | 21,000 | Sell* | 1.20 | 1.50 | 281.40 | O Ordinary |
18-Mar-24 | 08:34:10 | 1.34 | 250,000 | Sell* | 1.20 | 1.50 | 3,350 | O Ordinary |
18-Mar-24 | 08:32:40 | 1.30 | 58,852 | Buy* | 1.20 | 1.30 | 765.08 | O Ordinary |
18-Mar-24 | 08:27:36 | 1.30 | 10,808 | Buy* | 1.20 | 1.30 | 140.50 | O Ordinary |
18-Mar-24 | 08:24:57 | 1.30 | 5,520 | Buy* | 1.20 | 1.30 | 71.76 | O Ordinary |
18-Mar-24 | 08:23:15 | 1.299 | 19,245 | Buy* | 1.20 | 1.30 | 249.99 | O Ordinary |
18-Mar-24 | 08:19:43 | 1.30 | 50,000 | Buy* | 1.20 | 1.30 | 650.00 | O Ordinary |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
25-Jul-23 | 22-Jul-23 | Transfer To | James Simon Millen held the position of Executive Chairman at the time of this trade.James Simon Millen | 0.00 | 500,000 | 1,884,393 | |
18-Jul-23 | 14-Jul-23 | Transfer To | Christophe Chassagnole held the position of COO at the time of this trade.Christophe Chassagnole | 0.00 | 500,000 | 1,102,723 | |
29-Jun-21 | 28-Jun-21 | Transfer To | Christophe Chassagnole held the position of COO at the time of this trade.Christophe Chassagnole | 0.00 | 85,715 | 602,723 | |
21-May-21 | 21-May-21 | Transfer To | James Simon Millen held the position of CEO at the time of this trade.James Simon Millen | 0.00 | 242,287 | 1,384,393 | |
22-Mar-21 | 29-Jan-21 | Transfer To | James Simon Millen held the position of CEO at the time of this trade.James Simon Millen | 0.00 | 242,287 | 1,384,393 |
Physiomics is a leading oncology drug development consultancy using proprietary state of the artVirtual Tumour™ technology and other tools to predict and better understand the effects of cancer treatments. We work with partners developing cancer drugs to help them save time and money during pre-clinical and clinical development.